Home › Myelofibrosis › Maryland
Myelofibrosis clinical trials in Maryland
9 studies for Myelofibrosis are looking for participants at sites in Maryland.
Cities in Maryland
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- University of Maryland, Baltimore
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT04176198A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- American Oncology Partners PA Center for Cancer and Blood Disorders, Bethesda
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07357727Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06398457A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
- Johns Hopkins University, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07008118Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- John Hopkins Hospital, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT07441694A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Johns Hopkins Hospital, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 17, 2026 · NCT06034002A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Maryland Oncology Hematology - Independent of SCRI/ US Oncology, Columbia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 12, 2026 · NCT05980806SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Bethesda
- Massive Bio SYNERGY-AI site, Silver Spring
- and 1 more
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
- The Center for Cancer and Blood Disorders, Bethesda
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2025 · NCT06479135From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.